Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer - Current State and Evolving Standards

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Prostate-specific membrane antigen (PSMA) theranostics represent a significant advancement in prostate cancer management.
• PSMA-ligand positron emission tomography (PET)/computed tomography (CT) shows superior diagnostic accuracy compared to conventional imaging.
• Metastatic castration-resistant prostate cancer (mCRPC) management has been advanced by PSMA-based approaches.

Purpose of the Study:

• To evaluate the impact of PSMA-based theranostics in prostate cancer management.
• To highlight the diagnostic and therapeutic advancements offered by PSMA-ligand PET/CT and [177Lu]Lu-PSMA-617.
• To explore the integration of [177Lu]Lu-PSMA-617 in earlier stages of prostate cancer.

Main Methods:

• Review of clinical data and phase 3 trial evidence for PSMA-ligand PET/CT and [177Lu]Lu-PSMA-617 therapy.
• Analysis of diagnostic accuracy of PSMA-ligand PET/CT in various clinical settings.
• Assessment of survival end points and quality of life improvements with [177Lu]Lu-PSMA-617 therapy.

Main Results:

• PSMA-ligand PET/CT demonstrates superior diagnostic performance in prostate cancer.
• [177Lu]Lu-PSMA-617 therapy is established as a standard of care for mCRPC, improving survival and quality of life.
• Emerging data indicate safe and effective use of [177Lu]Lu-PSMA-617 in earlier disease stages.

Conclusions:

• PSMA-based theranostics are transforming prostate cancer care.
• Nuclear medicine plays a vital role in precision oncology for prostate cancer.
• [177Lu]Lu-PSMA-617 offers significant benefits across different stages of prostate cancer.